Mantle Cell Lymphoma

Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Lore Gruenbaum, PhD, discusses hot topics in mantle cell lymphoma, such as recently approved CAR T-cell therapies and where she sees the field moving next.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has granted traditional approval to brexucabtagene autoleucel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.

Tycel Phillips, MD, discusses how CAR T-cell therapies and bispecific antibodies could further affect mantle cell lymphoma management.

Data from China showed relma-cel yielded durable responses in patients with relapsed/refractory mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.

Tycel Phillips, MD, discusses key questions on optimal BTK inhibitor strategies in mantle cell lymphoma.

Real-world data suggest CD20 bispecific antibodies show activity after CD19 CAR T in mantle cell lymphoma, though durability of response remains unclear.

Ibrutinib plus bendamustine and rituximab prolonged PFS in patients with previously untreated mantle cell lymphoma who achieved a CR.

Ibrutinib plus venetoclax yielded sustained complete response rates and a favorable safety profile in relapsed/refractory mantle cell lymphoma.

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.

Patients with relapsed/refractory MCL had poor treatment outcomes with BTK inhibition, which decreased in quality as the line of therapy advanced.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.